Cellectar Biosciences Inc reports results for the quarter ended September 30 - Earnings Summary
Cellectar Biosciences Inc CLRB.OQ reported a quarterly adjusted loss of 40 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -83 cents. The mean expectation of four analysts for the quarter was for a loss of 37 cents per share. Wall Street expected results to range from -43 cents to -26 cents per share.
Reported revenue was zero; analysts expected zero.
Cellectar Biosciences Inc's reported EPS for the quarter was a loss of 40 cents.
The company reported a quarterly loss of $14.66 million.
Cellectar Biosciences Inc shares had fallen by 13.1% this quarter and lost 32.9% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts was unchanged in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for Cellectar Biosciences Inc is $13.50
This summary was machine generated from LSEG data November 18 at 10:02 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Sep. 30 2024 | -0.37 | -0.40 | Missed |
Jun. 30 2024 | -0.34 | -0.03 | Beat |
Mar. 31 2024 | -0.56 | -0.74 | Missed |
Dec. 31 2023 | -0.57 | -0.61 | Missed |
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
